November 24, 2025 Dataset Open Access

Mayer, Leonie

JSON Export

{"conceptdoi":"10.25592/uhhfdm.17970","conceptrecid":"17970","created":"2025-11-26T13:20:29.717359+00:00","doi":"10.25592/uhhfdm.17971","id":17971,"links":{"badge":"https://www.fdr.uni-hamburg.de/badge/doi/10.25592/uhhfdm.17971.svg","conceptbadge":"https://www.fdr.uni-hamburg.de/badge/doi/10.25592/uhhfdm.17970.svg","conceptdoi":"http://doi.org/10.25592/uhhfdm.17970","doi":"http://doi.org/10.25592/uhhfdm.17971"},"metadata":{"access_right":"open","access_right_category":"success","communities":[{"id":"uhh"},{"id":"uke"}],"creators":[{"affiliation":"Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany","name":"Mayer, Leonie","orcid":"0000-0001-7102-4358"}],"description":"<p><strong>Abstract</strong></p>\n\n<p>MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune responses remain detectable for at least 24 months after the third vaccination. &nbsp;Antibodies persisted at levels comparable to the peak response observed after the second vaccination and were able to cross-neutralize MERS-CoV spike mutants. Although the immune correlates of protection against MERS remain unknown, the observed durability of humoral and cellular immune responses supports the potential of MVA-MERS-S as a promising MERS vaccine candidate and highlights the importance of a booster dose in sustaining long-term immunity.</p>","doi":"10.25592/uhhfdm.17971","journal":{"title":"Nature Communications"},"keywords":["vaccine","Modified Vaccinia virus Ankara","Middle East respiratory sydrome coronavirus","immunogenicity"],"license":{"id":"CC-BY-4.0"},"notes":"This dataset includes the immunogenicity data of the manuscript.","publication_date":"2025-11-24","related_identifiers":[{"identifier":"10.25592/uhhfdm.17970","relation":"isVersionOf","scheme":"doi"}],"relations":{"version":[{"count":1,"index":0,"is_last":true,"last_child":{"pid_type":"recid","pid_value":"17971"},"parent":{"pid_type":"recid","pid_value":"17970"}}]},"resource_type":{"title":"Dataset","type":"dataset"},"title":"Two-year persistence of MERS-CoV-specific antibody and T cell responses  after MVA-MERS-S vaccination in healthy adults"},"owners":[852],"revision":3,"updated":"2025-12-01T17:15:59.622066+00:00"}